Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-associated Inflammatory Bowel Disease

  • Kono Masashi
    Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
  • Sakurai Toshiharu
    Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
  • Okamoto Kazuki
    Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
  • Nagai Tomoyuki
    Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
  • Komeda Yoriaki
    Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
  • Kashida Hiroshi
    Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
  • Minaga Kosuke
    Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
  • Kamata Ken
    Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
  • Takenaka Mamoru
    Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
  • Hagiwara Satoru
    Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
  • Watanabe Tomohiro
    Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
  • Nishida Naoshi
    Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan
  • Enoki Eisuke
    Department of Pathology, Kindai University Faculty of Medicine, Japan
  • Inoue Hiroaki
    Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Japan
  • Matsumura Itaru
    Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Japan
  • Kudo Masatoshi
    Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Japan

Abstract

<p>Autoimmune diseases including inflammatory bowel disease (IBD) occur in association with myelodysplastic syndrome (MDS). MDS-associated IBD frequently demonstrates a complicated course. We herein report the first case with MDS-associated IBD that was successfully treated with ustekinumab (UST), an anti-interleukin (IL) 12/23p40 monoclonal antibody. A 63-year-old man with a 7-year history of MDS was referred for examination of diarrhea, abdominal pain and fever. A blood examination revealed a marked elevation of C-reactive protein. Colonoscopy showed multiple ulcers in the terminal ileum. He was resistant to anti-tumor necrosis factor (TNF)-α antibody and azacitidine. Subsequently, UST treatment reduced colonic IL-17 and IL-6 expression and the patient currently maintains a state of remission. </p>

Journal

  • Internal Medicine

    Internal Medicine 58 (14), 2029-2033, 2019-07-15

    The Japanese Society of Internal Medicine

References(14)*help

See more

Related Projects

See more

Details 詳細情報について

Report a problem

Back to top